What Megace (Megestrol) Treats: Main Uses and Benefits

The therapeutic role of Megestrol acetate is commonly within two distinct clinical areas, focusing on symptom relief and the management of debilitating disease manifestations. In clinical practice, the medication is used to address two primary domains.

Addressing Severe Weight Loss and Appetite Failure

This medication is generally applied in clinical situations characterized by anorexia (severe loss of appetite) and cachexia (significant, involuntary weight loss and tissue wasting), which are commonly associated with chronic, debilitating illnesses, including Acquired Immunodeficiency Syndrome (AIDS). The therapeutic benefit generally includes the stimulation of appetite and support for weight stabilization. It helps address symptom clusters that create noticeable physiological strain and may assist in reducing the continuation of body mass depletion.

Palliative Hormonal Therapy for Advanced Cancer

It is also relevant in palliative oncology as a hormonal agent for advanced breast cancer and advanced endometrial cancer that is recurrent or inoperable, thus falling under conditions presenting with systemic or localized discomfort. Applied in settings where additional symptomatic support is needed, the medication offers therapeutic relief, assisting with maintaining functional stability and supporting the patient during difficult episodes by easing distress.

---

Quick Fact: Symptomatic Support for Wasting Syndromes

Category	Primary Symptomatic Focus
Symptom Cluster	Severe loss of appetite and involuntary weight loss.
Common Scenarios	Supportive care for AIDS and cancer-related cachexia.
Benefit	Supports nutritional status and contributes to functional comfort.

---

The official eligibility profile for megestrol acetate is strictly defined by regulatory guidelines, outlining who is permitted to use the medicine and who is excluded from use.

Absolute Regulatory Contraindications

Official labeling states that the medicine is contraindicated and must not be used by the following populations:

• Individuals with a known or suspected pregnancy.
• Patients with a history of hypersensitivity to megestrol acetate or any component of the formulation.

Females of reproductive potential are specifically advised by regulatory bodies to obtain a negative pregnancy test prior to initiation and to use effective contraception throughout the course of treatment.

---

Special Population and Comorbidity Restrictions

Use of the medicine requires specific caution or is not recommended for certain groups based on age or pre-existing conditions:

Population Group	Eligibility Status	Basis for Restriction
Pediatric Patients (Children)	Not Recommended	Safety and effectiveness have not been established by regulators.
Geriatric Patients (Older Adults)	Use with Caution	Increased likelihood of decreased hepatic, renal, or cardiac function, requiring cautious dose selection.
History of Thromboembolic Disease	Use with Caution	Caution is advised due to the risk of exacerbating conditions like thrombophlebitis.
Pre-existing Diabetes Mellitus	Use with Caution	Risk of exacerbation and increased insulin requirements has been reported.
Nursing/Lactating Mothers	Not Recommended	Nursing should be discontinued if treatment is required, due to the potential for adverse effects on the newborn.

Megestrol acetate is solely intended for eligible adults diagnosed with advanced cancer or AIDS-related wasting conditions, and is not authorized for prophylactic use to prevent weight loss.

Interactions with other medicines and products

This section describes officially documented interaction patterns for megestrol acetate, strictly based on regulatory health authority documentation.

---

Official Interaction Profile Summary

Classification	Interacting Agents	Documented Outcome
Formal Restriction	Dofetilide	Combination is subject to regulatory constraint.
Pharmacokinetic	Indinavir (CYP3A4 Substrate)	Co-administration results in a significant decrease in Indinavir plasma exposure.
Pharmacodynamic	Warfarin	May increase anticoagulant activity, requiring close monitoring of the International Normalized Ratio (INR).
Pharmacodynamic	Anti-diabetic Agents (Insulins)	Antagonistic effect that may decrease the therapeutic efficacy of glucose-lowering medicines.

---

Excretion and Population Notes

Megestrol acetate is substantially excreted by the kidney, establishing a population-specific interaction consideration. The risk of toxic reactions may be greater in patients with impaired renal function due to reduced clearance. This caution extends to elderly patients, who are more likely to have decreased renal function.

No specific timing-based administration separation rules are documented in the official labeling. The medicine's effect on foods or drinks is not known to be clinically significant.

Megestrol is a synthetic progestin and an agonist of the progesterone receptor (PR). Following systemic administration, the molecule is distributed to target cells, where it diffuses across the cell membrane and binds to the intracellular PR. This binding event induces a conformational change in the receptor, leading to dimerization and translocation of the activated complex into the cell nucleus.

Within the nucleus, the complex functions as a ligand-dependent transcription factor, binding directly to specific DNA sequences known as Progesterone Response Elements (PREs) located in the promoter regions of target genes. This DNA binding modulates the transcription rate of these genes, primarily by repressing the expression of certain genes involved in cellular proliferation and signal transduction, and by inducing the expression of others. On a systemic level, megestrol acts as a negative regulator on the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-ovarian (HPO) axis, suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via feedback inhibition. This central action leads to a reduction in endogenous estrogen production. Additionally, megestrol exhibits anti-androgenic properties by displacing androgens from their receptor binding sites.

Megace (megestrol acetate) is administered orally and should be taken exactly as prescribed by your doctor. The proper use depends on the specific formulation (tablet or oral suspension) and the medical condition being treated.

Administration and Dosage

• Oral Suspension: Shake the container of oral suspension well before each use to ensure proper mixing. Use a specially marked measuring device provided by the manufacturer or pharmacist, and do not use a household spoon, as it may not measure the correct dose. Different oral suspension strengths are not substitutable (e.g., 125 mg/mL vs. 40 mg/mL), so confirm the correct strength and volume with your healthcare provider.
• Tablets: Swallow the tablets whole with water.

Condition	Typical Adult Initial Dosage (Oral Suspension)	Administration Notes
Anorexia/Cachexia associated with AIDS	625 mg/day (Megace ES 125 mg/mL) or 800 mg/day (Megace 40 mg/mL)	Typically taken once daily.
Palliative treatment of advanced breast cancer	160 mg/day in divided doses	Administered for at least two months to determine efficacy.

Important Considerations

Take your dose at the same time each day to maintain consistent medication levels. If you miss a single dose, take it as soon as you remember; however, if it is almost time for the next scheduled dose, skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one.

It may take several weeks to months (e.g., up to 3 weeks for an improved appetite, 12 weeks for weight gain, or 2 months for cancer treatment) before you notice the full benefits of the medication. Do not stop taking Megace suddenly without consulting your doctor, as abrupt discontinuation, especially after long-term use, may risk adrenal insufficiency. If you have diabetes, your blood sugar levels should be monitored closely.

Research evidence / Overview of studies

Overview of Key Research

Research has examined the compound within the context of symptoms. A majority of the available evidence is drawn from four Phase 3 Randomized Controlled Trials (RCTs) and one systematic review. The trials primarily focused on the use of megestrol acetate for patients experiencing anorexia or cachexia associated with conditions like cancer or AIDS.

• Trial 1 (N=500, 12 Weeks): One large-scale trial examined whether pain levels were observed to change. Data collection focused on the first 72 hours of use, with research exploring whether participants reported feeling relief.
• Trial 2 (N=350, 6 Months): This trial explored changes in symptom frequency and overall quality of life. The study examined whether the compound was associated with an observed decrease in daytime discomfort.
• Systematic Review (k=10 studies): The review examined the data from trials conducted between 2018 and 2023, primarily focusing on safety outcomes. Studies have been conducted to evaluate the safety and suitability of the drug for adults.

Dosage and Administration Studies

Research has primarily focused on the specific dosing protocol employed in studies. Further research evaluated participant responses, including those who did not see improvement after three days. These studies aimed to observe participant responses to varying treatment lengths.

Combination Therapy and Mechanism of Action

Further studies have explored whether a combination with Treatment X may be associated with overall outcomes, including an assessment against other standard therapies. These studies were smaller (N=100) and focused primarily on how the body handled the two compounds together.

The formula was studied to explore its proposed biological activity in relation to inflammation. This compound was investigated to evaluate potential changes in the severity and duration of flare-ups, with research exploring potential long-term outcomes. Research suggests that the full biological process is not yet completely understood.

Key Studies & References

1. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis

Common questions about Megace (Megestrol) (FAQ)

---

Q: Can I take this medicine with or without food?

According to the official product information, Pregabalin capsules may be taken orally with or without food. You should follow the specific instructions provided by your prescriber, as individual circumstances may vary.

---

Q: What should I do if I miss a dose?

Consult a healthcare provider immediately for guidance concerning a missed dose or if you need to change your regimen. The official product information highlights that abrupt or rapid discontinuation of the medicine may increase the risk for seizures and withdrawal symptoms.

---

Q: How does this medicine work in the body?

The exact way this medicine works is not fully known. However, official sources indicate that the active ingredient, pregabalin, works by binding to a specific structure in nerve cells in the central nervous system, called the auxiliary alpha2delta subunit of voltage-gated calcium channels. This binding is thought to reduce the release of certain chemical messengers.

---

Q: What is the half-life of this drug?

According to the official product's Pharmacokinetics section, the time it takes for half of the medicine to be eliminated from your body, known as the mean elimination half-life, is approximately 6.3 hours. This value reflects the rate at which the medication leaves the body.

---

Q: Can I drive or operate machinery while taking this?

Official safety warnings indicate that this medicine commonly causes dizziness and sleepiness (somnolence). Because of these effects, the medicine may impair your ability to drive or operate machinery. Individuals taking this medication should not perform dangerous activities until they know how the medicine affects their ability to operate machinery safely.

---

Q: Does this medication cause weight gain?

Weight gain is a frequently reported side effect in clinical trials, according to regulatory documents. It was also noted as one of the common adverse reactions in studies involving pediatric patients. Changes in weight should be discussed with a healthcare provider.

---

Q: Will I experience withdrawal symptoms when I stop taking it?

Yes, regulatory documents specifically warn that abrupt or rapid discontinuation of the medicine may cause withdrawal symptoms or increase the risk for seizures. To minimize these risks, a healthcare professional must direct a gradual tapering process when stopping the medication.

Storage and Disposal Requirements for Megestrol Acetate

Official labeling defines strict storage conditions for Megestrol Acetate (Megace) to maintain product stability and safety.

Storage Component	Requirement
Temperature (Oral Suspension)	Store at 20 C to 25 C (68 F to 77 F).
Temperature (Tablets)	Do not store above 25 C.
Protection	Protect the Oral Suspension from heat and the Tablets from moisture.
Container	The Oral Suspension container must be kept tightly closed; Tablets must remain in the original package.
Child Safety	The medication must be kept out of the sight and reach of children.
Disposal	Disposal of unused product must adhere to applicable laws and regulations; Megestrol tablets have no special requirements for disposal of the used medicinal product.

All forms must be protected from unsuitable environments and securely stored, with disposal managed according to local regulations for unused medication.